Oncolytic Viruses
Manufacturing Oncolytic Viruses: Where Complexity Demands Experience
Mathias Kahl
IDT Biologika
PAO-09-26-CL-01Sep 17, 2026
CCS and CMC
Packaging Returns to the Center of CMC Strategy
Pharma's Almanac
PAO-09-26-PA-10Sep 14, 2026
iPSCs
For iPSC Therapies, Manufacturing Consistency May Mean Preserving Function
Pharma's Almanac
PAO-09-26-PA-09Sep 11, 2026
AI-Optimized CLD
From Screening to Design: Can Production Cell Lines Become Programmable Platforms?
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-19Jul 20, 2026
BsAbs
Why Bispecific Antibody Architecture Is a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-06-26-PA-01Jun 2, 2026
Continuous VV
The Stepwise Future of Continuous Viral Vector Manufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-12Jun 1, 2026
Psychedelics CMC
The CMC Challenge for Psychedelic Drugs
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-21May 22, 2026
Conjugation
Why ADC Conjugation Strategy Is Now a CMC Decision
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-18May 20, 2026
ADC Linkers
Linker Chemistry as the Hidden Determinant of ADC Success
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-26-PA-10May 8, 2026
Sustainable CIP
Sustainable Clean-in-Place: Rethinking Legacy Chemistry in Modern Biomanufacturing
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-CL-02May 7, 2026
Neuro CMC
Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics
David Alvaro, Ph.D.
Pharma's Almanac
PAO-04-26-PA-03Apr 3, 2026
CMC and Investment
Where Capital Meets CMC: The Emerging Role of CDMOs in Investor Risk Assessment
David Alvaro, Ph.D.; Daniel Smith, Ph.D.
Pharma's Almanac
PAO-01-26-NI-15Jan 15, 2026
Platforms
Built for Speed and Scale: How CDMO Cell Line Platforms Are Reshaping Biologic Development
David Alvaro, Ph.D.
Pharma's Almanac
PAO-07-25-NI-05Jul 15, 2025
CLD
Advancing Biologics Development With Next-Generation Cell Line Development
Woo Chi, Ph.D.; Yingji Jin, Ph.D.; Jaeeun Kim
Samsung Biologics
PAO-06-25-CL-06Jun 16, 2025
PPQ
Fast Path to Market: Going from GMP1 to PPQ in Just 12 Months
Jessica Feldman, Ph.D.; Henning Gerschewski
Rentschler Biopharma SE
PAO-10-24-CL-12Dec 2, 2024
CDMO
Revolutionary CDMO Wheeler Bio Appoints Patrick Lucy as CEO
David Alvaro, Ph.D.
Pharma's Almanac
PAO-10-24-CL-08Oct 11, 2024
Developability
Mitigating Early Development Risks with Samsung Biologics DEVELOPICK™ Platform
Heonchang Lim
Samsung Biologics
PAO-09-24-CL-04Sep 4, 2024
Digitalization
Radical Bioprocessing Efficiencies and Cost Reductions — The Next Wave of Biopharmaceutical Innovation
Michael Sokolov, Ph.D.
DataHow
PAO-08-24-CL-02Aug 26, 2024
IND Enablement
IND Enablement and Drug Product Development – Mitigating Risk and Accelerating through the "Valley of Death"
Johannes Clemens
Coriolis Pharma
PAO-08-24-CL-07Aug 16, 2024
CDMO Model
Rethinking the Conventional CDMO Model
Wheeler Bio
PAO-08-24-CL-04Jul 29, 2024